Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01, Zacks reports.
Atossa Therapeutics Price Performance
Shares of ATOS stock traded down $0.00 during trading hours on Friday, reaching $0.70. 434,447 shares of the company traded hands, compared to its average volume of 984,925. The firm has a 50-day moving average price of $0.79 and a 200 day moving average price of $1.10. The company has a market cap of $89.93 million, a P/E ratio of -3.16 and a beta of 1.20. Atossa Therapeutics has a 12-month low of $0.66 and a 12-month high of $2.31.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the company. HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research note on Wednesday. Ascendiant Capital Markets boosted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a "buy" rating in a research report on Monday, December 9th.
Check Out Our Latest Report on Atossa Therapeutics
Institutional Investors Weigh In On Atossa Therapeutics
An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE lifted its position in Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 51.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 111,475 shares of the company's stock after purchasing an additional 37,809 shares during the period. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.74% of the stock is owned by institutional investors.
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Further Reading
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
